Analysts expect Sigyn Therapeutics, Inc. to report revenue of 2.01 M for 2017, against a range of 1.85 M to 2.18 M.
| Metric | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|
| Reported (Actual) | - | - | ||
| High Estimate | 2.18 M | 7.10 M | ||
| Low Estimate | 1.85 M | 6.39 M | ||
| Consensus Estimate | 2.01 M | 6.74 M |
Analysts expect Sigyn Therapeutics, Inc. to report earnings per share of -444.31 for 2017, against a range of -459.90 to -428.72.
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | ||||
| High Estimate | -428.72 | -260.75 | ||||
| Low Estimate | -459.90 | -298.03 | ||||
| Consensus Estimate | -444.31 | -279.39 |